Raxibacumab, medically designated as PAmAb ABthrax, signifies a novel therapeutic approach to the disease . This monoclonal protein, developed by the company , uniquely binds to the protective component of Bacillus anthracis, demonstrably neutralizing its capacity to trigger disease . The process of Raxibacumab entails blocking toxin attachment to